

DEP & REF
Room 307

Express Mail No.: EL 477 035 130 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#4/ Reg for
Refund
04-08-02

Application of: Roemer et al.

Application No.: 10/032,585

Group Art Unit: To be Assigned

Filed: December 20, 2001

Examiner: To Be Assigned

For: GENE DISRUPTION TECHNOLOGIES FOR DRUG
TARGET DISCOVERY

Attorney Docket No.: 10182-016-999

REQUEST FOR REFUND PURSUANT TO 37 C.F.R. § 1.28(a)

Assistant Commissioner for Patents
Washington, D.C. 20231

Attention: Refund Section, Accounting Division

Sir:

Applicants note that a filing fee of \$4950.00 has been received by the U.S. Patent and Trademark Office in connection with the filing of the above-identified utility patent application (see attached copy of the Filing Receipt). Applicants request a refund of one half of the filing fees that were paid, i.e., \$2475.00. Submitted concurrently herewith is a Verified Statement (Declaration) Claiming Small Entity Status for Elitra Pharmaceuticals, Inc., an entity having certain rights in the invention. Pursuant to 37 C.F.R. § 1.28(a), Applicants request a refund of the excess amount within three months of its timely payment.

Accordingly, please refund the excess by crediting \$2475.00 to Deposit Account No. 16-1150.
A copy of this sheet is enclosed.

Respectfully submitted,

Date: March 13, 2002


Laura A. Coruzzi ^{40,258}
30,742
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures



UNITED STATES PATENT AND TRADEMARK OFFICE



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/032,585	12/20/2001	1636	4950	10182-016-999	7	77	29

CONFIRMATION NO. 8340

20583
PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711

FILING RECEIPT



OC000000007547636

Date Mailed: 02/27/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

- ✓ Terry Roemer, Montreal, CANADA;
- ✓ Bo Jiang, Montreal, CANADA;
- ✓ Charles Boone, Toronto, CANADA;
- ✓ Howard Bussey, Westmount, CANADA;
- ✓ Kari L. Ohlsen, San Diego, CA;

DIS-3/20/02
FOR-8/20/02
EXP-12/20/08

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/792,024 02/20/2001
AND CLAIMS BENEFIT OF 60/259,128 12/29/2000
AND CLAIMS BENEFIT OF 60/314,050 08/22/2001

Foreign Applications

If Required, Foreign Filing License Granted 02/27/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Gene disruption methodologies for drug target discovery ✓

REFERRED TO	<i>M-Ryan</i>
REC'D	
MAR 05 2002	
PENNIE & EDMONDS	
O.K. for filing	